UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)
Roivant Sciences Ltd.
(Name of Issuer)
Common Shares, par value $0.0000000341740141 per share
(Title of Class of Securities)
G76279101
(CUSIP Number)
April 2, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| 1 | NAMES OF REPORTING PERSONS
Sumitomo Chemical Co., Ltd. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Japan | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
0 | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
0 | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.00% | |||||
| 12 | TYPE OF REPORTING PERSON CO | |||||
| 1 | NAMES OF REPORTING PERSONS
Sumitomo Pharma Co., Ltd. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Japan | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
0 | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
0 | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.00% | |||||
| 12 | TYPE OF REPORTING PERSON CO | |||||
| Item 1(a). | Name of Issuer: |
Roivant Sciences Ltd. (the “Issuer”).
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Roivant Sciences Ltd.
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
| Item 2(a). | Name of Person Filing: |
Sumitomo Chemical Co., Ltd. (“Sumitomo Chemical”).
Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”).
(Each a “Reporting Person,” and collectively, the “Reporting Persons”).
| Item 2(b). | Address of Principal Business Office or, if None, Residence: |
Sumitomo Chemical:
7-1, Nihonbashi 2-chome
Chuo-ku, Tokyo
103-6020, Japan
Sumitomo Pharma:
6-8 Doshomachi 2-chome
Chuo-ku, Osaka
541-0045, Japan
| Item 2(c). | Citizenship: |
See Row 4 of the cover page for each Reporting Person, respectively.
| Item 2(d). | Title of Class of Securities: |
Common Shares, par value $0.0000000341740141 per share of the Issuer (“Common Shares”).
| Item 2(e). | CUSIP Number: |
G76279101
| Item 3. | If this Statement is Filed Pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a: |
Not applicable.
| Item 4. | Ownership. |
(a) Amount beneficially owned: See Row 9 of the cover pages for each Reporting Person, respectively.
(b) Percent of class: See Row 11 of the cover pages for each Reporting Person, respectively.
(c) Number of shares as to which the person has:
| (i) | Sole power to vote or to direct the vote: See Row 5 of the cover pages for each Reporting Person, respectively. |
| (ii) | Shared power to vote or to direct the vote: See Row 6 of the cover pages for each Reporting Person, respectively. |
| (iii) | Sole power to dispose or to direct the disposition of: See Row 7 of the cover pages for each Reporting Person, respectively. |
| (iv) | Shared power to dispose or to direct the disposition of: See Row 8 of the cover pages for each Reporting Person, respectively. |
| Item 5. | Ownership of Five Percent or Less of Class. |
The Reporting Persons have ceased to be 5% beneficial owners of the Common Shares of the Issuer. Therefore this Schedule 13G Amendment is the final filing for the Reporting Persons.
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
| Item 10. | Certifications. |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: April 2, 2024 | ||
| Sumitomo Chemical Co., Ltd. | ||
| By: | /s/ Yuji Kato | |
| Name: | Yuji Kato | |
| Title: | Executive Officer, Corporate Planning Office | |
| Sumitomo Pharma Co., Ltd. | ||
| By: | /s/ Yutaka Wakemi | |
| Name: | Yutaka Wakemi | |
| Title: | Executive Officer, Vice President, Head of Global Corporate Strategy | |
